Belimumab combined with standard therapy demonstrated significant improvements in mucocutaneous symptoms in patients with systemic lupus erythematosus (SLE) compared with placebo with standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback